ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO (Site 1560)

The trials here

What the trial at this site is about, from its registry record.

Conditions

• Bladder cancer

Running trials

• Active, not recruiting

  Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

  NCT03711032· Phase 3· Merck Sharp & Dohme LLC· Source